Premium
A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies
Author(s) -
Rozga Jacek,
Umehara Yutaka,
Trofimenko Andrey,
Sadahiro Tomohito,
Demetriou Achilles A
Publication year - 2006
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2006.00355.x
Subject(s) - medicine , fulminant hepatic failure , liver transplantation , hepatic encephalopathy , inflammation , renal replacement therapy , bridge to transplantation , liver regeneration , transplantation , pharmacology , regeneration (biology) , cirrhosis , heart transplantation , biology , microbiology and biotechnology
There is a need to develop artificial means of liver replacement and/or assistance with the aim of either supporting patients with borderline functional liver cell mass until their liver regenerates, or until a donor liver becomes available for transplantation. Selective plasma filtration is a novel approach to blood purification therapy designed to reduce the level of circulating toxins of hepatic and renal failure, mediators of inflammation and inhibitors of hepatic regeneration. The results of preclinical studies indicate that treatment of pigs with experimentally‐induced fulminant hepatic failure is safe and effective in extending survival time and arresting brain swelling. In addition, the amount of ammonia, aromatic amino acids, IL6, TNFα and C3a removed during the 6‐h treatment in the present study was higher by 34% to 175% than the total plasma content of those substances at the start of therapy.